![]() ![]() Previously, he served as Chief Financial Officer since joining the company in 2014. Mendel has served as GenMark’s Chief Operating Officer since February 2019. “In the upcoming year, we will continue to drive sustainable revenue growth, gross margin expansion and improved profitability.” “I am confident that we have the right technology, strategy, and team in place at GenMark to be the leader in rapid multiplex molecular testing,” added Scott Mendel, President and Interim Chief Executive Officer. “We are confident that Scott’s experience at the company and track record leading its financial, manufacturing and product development organizations will provide a seamless transition.” Today the company stands well positioned to take share in a rapidly growing market,” said Kevin O’Boyle Chairman of the GenMark Board of Directors. He led the company through multiple pivotal phases of growth including the FDA approval and launch of both the XT-8 and ePlex systems and their corresponding assays. “On behalf of the entire Board of Directors, I would like to thank Hany for his leadership throughout his tenure at GenMark. A search has commenced to identify a permanent CEO.Ĭoncurrently Kevin O’Boyle has been appointed Chairman of the Board and James Fox, PhD., GenMark’s prior Chairman, will remain on the Board as a non-executive director. ![]() Hany Massarany has stepped down as President and CEO and as a member of the company’s Board of Directors, effective immediately. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel, Chief Operating Officer, has been appointed Interim President and Chief Executive Officer effective immediately. 10, 2020 (GLOBE NEWSWIRE) - GenMark Diagnostics, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |